Share this article

PhaseBio Pharmaceuticals, a clinical-stage biotechnology company, has begun patient dosing in a multicentre Phase IIb trial to evaluate use of Glymera for the treatment of uncontrolled type 2 diabetes.

The randomised placebo and active comparator controlled Phase IIb trial is designed to evaluate the efficacy and safety of three doses of once-weekly Glymera, compared to a matched placebo and an active comparator.

PhaseBio chief scientific officer Dr Craig Rosen said; "We are extremely pleased at the rapid progress we have made since our first IND filing in October 2010 to make once weekly Glymera a competitive player in the GLP-1 space, as evidenced by very strong efficacy data that gives us, as well as our investors, the confidence that we will be able to establish product differentiation from other GLP-1 agonists with improved tolerability and efficacy in this Phase IIb trial."

The study, which will enrol approximately 600 patients with type 2 diabetes (hemoglobin A1c 7% – 11%) inadequately controlled with diet and exercise, metformin, a sulfonylurea or a combination of metformin/sulfonylurea, is expected to completed by the third quarter of 2013.

As a result of encouraging Phase I/IIa results, PhaseBio raised an additional $23m in May 2012 to support Phase IIb clinical testing of Glymera for the treatment of type 2 diabetes.

Diabetes mellitus type 2, formerly non-insulin-dependent diabetes mellitus (NIDDM) or adult-onset diabetes, is a metabolic disorder characterised by high blood glucose, insulin resistance and relative insulin deficiency.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData